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Abstract
Background We present a comprehensive analysis of both
therapy-induced severe late toxicity and outcome in a cohort of
cervical cancer patients following radiation who were treated
according to current guidelines and discuss the methodologic
problems of systematically reporting these cases. We intro-
duce a revised concept of reporting treatment failure.
Patients and methods The records of 128 cervical cancer
patients who received radiation from 2003 to 2008 were
reviewed.
Results Thirteen patients (10.2%) developed severe late
toxicity. The combination of heavy smoking and cardio-
vascular diseases was found to be a significant contributing
factor (HR 6.55, 95% CI 0.99–43.49, p = 0.048). Thirty
patients (23.4%) experienced treatment failure. Of these,
12 (9.4%) were defined to have persistent disease, and 18
(14.0%) developed recurrent disease. Patients with recur-
rent disease had significantly better survival time
(p \ 0.001). Compared with the persistence subgroup, they
had significantly more often multiple sites of relapse (66.7
vs. 8.3%, p = 0.002) and the sites were more often diag-
nosed outside the pelvis (70.7 vs. 7.7%, p \ 0.001). Early
disease stages (OR 4.46, 95% CI 1.87–10.63, p \ 0.001)
and severe late toxicity (p = 0.037) were found to be
significant factors for an improved disease-free survival.
Conclusions A comprehensive depiction of both late
therapy-related toxicity and treatment failure requires
precise clinical descriptions and analyses of the clinical
courses. Our new concept to differentiate treatment failure
following radiotherapy in cervical cancer into persistent
and recurrent disease permits a clear differentiation
between distinct subgroups of patients with regard to
prognosis and clinical presentation and will lead to a more
precise description of these cases in the future.
Keywords Cervical cancer  Radiotherapy 
Chemoradiation  Outcome  Recurrence  Late toxicity
Introduction
Chemo-radiotherapy (CRT) has been established as the
standard of care in the treatment of advanced cervical
cancer for the last 10 years [1–5]. The meta-analyses which
evaluated CRT trials concluded uniformly that there were
insufficient data available to assess the frequency of serious
late toxicity associated with this therapeutic approach
[1–5]. Data on late toxicity were not recorded for the
majority of trials, and where included, substantial infor-
mation was missing. In addition, the clinical picture of late
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toxicity in individual patients were not described in detail
and underreporting may be assumed [1, 4]. In this paper,
we report our centre’s outcome data with CRT and present
an analysis of late toxicity following CRT and its
management.
Materials and methods
Study cohort
Between January 2003 and April 2008, 126 newly diag-
nosed patients with locally advanced cervical cancer,
International Federation of Gynecology and Obstetrics
(FIGO) stages IB2-IVA, and two patients with pelvic
recurrences of early-stage cervical cancer were treated
within the North London Gynaecological Cancer Network.
Radiotherapy was administered at the Department of
Oncology of the University College London Hospital
(London, UK). From the entire study cohort of 128
patients, 121 (94.5%) were treated with concomitant CRT.
Seven patients (5.5%) received radiotherapy only.
The clinicopathologic, treatment and outcome charac-
teristics of the patients included in the study are summa-
rized in Table 1. All patients were initially staged with
clinical examination under anaesthesia (EUA, including
cystoscopy), magnetic resonance imaging (MRI) of the
pelvis and computed tomography (CT) of the abdomen and
the chest. In 48 patients (37.5%), para-aortic lymph nodes
were histologically examined after retroperitoneal surgical
Table 1 Clinicopathologic
characteristics of 128 patients
who had radiation in cervical
cancer at the North London
Gynaecological Cancer
Network: entire study group and
the subgroups of patients who
had severe late toxicity after
radiation, and those who had
persistent or recurrent disease
FIGO Fe´de´ration International
de Gyne´cologie et d‘
Obste´trique (International
Federation of Gynecology and
Obstetrics), CR concomitant
CRT
Entire
study
group
n = 128
Patients with
severe late
toxicity
n = 13
Patients with
persistent
disease
after
radiation
n = 12
Patients with
recurrent
disease
after
radiation
n = 18
Age (years) Mean 48.5
(range
22–89)
Mean 55.0
(range
27–78)
Mean 50.0
(range
31–81)
Mean 48.5
(range
28–71)
FIGO stage at presentation (%)
Stage I 22 (17.2) 1 (7.7) – 2 (11.1)
Stage II 70 (54.7) 6 (46.1) 3 (25.0) 9 (50.0)
Stage III 31 (24.2) 4 (30.8) 7 (58.3) 6 (33.3)
Stage IVA 5 (3.9) 2 (15.4) 2 (16.7) 1 (5.6)
Paraaortal nodal status (%)
Histologically positive 9 (7.0) 2 (15.4) – 2 (11.1)
Histologically negative 39 (30.5) 2 (15.4) – 5 (27.8)
No surgical staging 80 (62.5) 9 (69.2) 12 (100.0) 11 (61.1)
Histological type (%):
Squamous-cell carcinoma 96 (75.0) 9 (69.2) 11 (91.7) 12 (66.7)
Adenocarcinoma 29 (22.7) 4 (30.8) 1 (8.3) 6 (33.3)
Small-cell carcinoma 3 (2.3) – – –
Radiotherapy alone 7 (5.5) – 2 (16.7) 1 (5.6)
Concomitant CRT 121 (94.5) 13 (100.0) 10 (83.3) 17 (94.4)
After radical hysterectomy 9 (7.0) 3 (23.1) – 2 (11.1)
After simple hysterectomy 5 (3.9) 1 (23.1) – –
After neoadjuvant chemotherapy 27 (21.1) 1 (7.7) 4 (33.3) 3 (16.7)
Concurrent anamnestic conditions (%)
Heavy smoking ([10 cigarettes/day) 30 (23.4) 6 (46.1) 3 (25.0) 5 (27.8)
Cardiovascular diseases 26 (20.3) 5 (38.5) 3 (25.0) 4 (22.2)
Outcome status in October 2009
Alive, no evidence of disease 95 (74.3) 13 (100.0) 1 (8.3) 1 (5.6)
Alive with recurrent/progressive
disease
3 (2.3) – – 3 (16.7)
Dead, cervical cancer 25 (19.5) – 11 (91.7) 14 (77.7)
Dead, intercurrent illness 5 (3.9) – – –
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exploration. This procedure was introduced into the stan-
dard staging protocol in 2005. In nine cases (7.0%), adju-
vant CRT was delivered after radical hysterectomy for
apparently early stage disease. Two patients (1.6%)
received CRT as salvage treatment for pelvic recurrences
after previous surgery for early-stage disease.
Radiotherapy
Prior to 2007, radiotherapy was planned using a conven-
tional simulator and information from pelvic MRI scan.
Since 2007, all patients undergo CT simulation and three-
dimensional conformal planning. Radiotherapy was given
according to defined protocols as follows:
(a) patients who received primary radiotherapy (n = 112,
87.5%): external beam radiation to the pelvis
(50.4 Gy/28 fractions/5.5 weeks/10 MV photons)
and intracavitary brachytherapy using an intrauterine
tube and ovoid system (15 Gy/2 fractions/HDR/point
A). Where parametrial invasion was evident, a further
boost (5.4 Gy/3 fractions) was delivered to the pelvic
side wall.
(b) Patients who underwent adjuvant radiotherapy fol-
lowing hysterectomy (n = 14, 10.9%): external beam
radiation to the pelvis (45 Gy/25 fractions/5 weeks/
10 MV photons) and vault brachytherapy (13 Gy/2
fractions/HDR/0.5 cm from surface of applicator).
(c) Patients who underwent CRT for pelvic recurrence
after previous radical hysterectomy (n = 2, 1.6%):
external beam radiation to the pelvis as per (a) and
vault brachytherapy as per (b).
No central shielding is used in our protocol.
Concomitant chemotherapy
One hundred twenty-one patients received concomitant
chemotherapy. One hundred and eighteen patients received
weekly cisplatin at 40 mg/m2 and three patients received
concomitant carboplatin and etoposide for small cell carci-
noma. Of these, 96 patients (82.1%) received at least five
cycles, 14 patients (12.0%) received four cycles, three
patients (2.5%) three cycles and one patient (0.9%) two
cycles. Twenty-seven patients (21.1%) received neoadjuvant
chemotherapy with weekly carboplatin (AUC 2) and pac-
litaxel (80 mg/m2) for 6 weeks within a clinical trial [6].
Acute toxicities were managed effectively such that all
patients completed their radiation without interruption.
Follow-up
Three months after completion of treatment, an MRI of the
pelvis is performed at our institution to document the
response to treatment. Thereafter, patients are clinically
evaluated every 3 months for the first 2 years, every
4 months during the third, and then every 6 months. A
routine follow-up visit includes a patient history and
complete physical examination including inspection of the
cervix or the vaginal vault and bimanual pelvic examina-
tion. During the follow-up, routine use of imaging tech-
niques is not performed; these are only performed to
investigate clinical suggestions of recurrent disease or in
the management of therapy-related side effects and
toxicities.
At the conclusion of data collection in October 2009,
there was complete follow-up information available for all
patients included in this study.
Late toxicity
Late toxicity was defined as that occurring more than
90 days after the first day of radiotherapy. In order to
categorize these, we used the Franco-Italian glossary
score which describes five grades of increasing sever-
ity: grade 0 has no complications, grade 1 mild, grade
2 moderate complications with patients able to main-
tain normal activity, grade 3 severe complications
requiring surgery or causing permanent damage and
grade 4 complications resulting in treatment-related
death [7].
Type, site and detection method of treatment failure
For patients who had treatment failure, we differentiated
between persistent and recurrent disease.
1. Persistence was defined as disease which either
progressed during treatment or that which became
clinically evident within 6 months of completion of
therapy in the irradiated central (i.e., cervix, uterus,
vaginal apex/vault) and/or pelvic region.
2. Recurrence was defined as disease at any site, becom-
ing clinically evident C6 months after completion of
therapy where previous routine post-treatment radio-
logic examination revealed a complete response.
Newly detected distant metastases and extra-pelvic
disease, which were not evident at initial presentation,
were also considered as recurrent disease, even if they
were found within the 6 months period after comple-
tion of treatment.
The procedure to distinguish two prognostically different
groups of treatment failure on the basis of a 6-month period
of recurrence-free survival after completion of therapy
refers to a similar and universally established differentia-
tion in ovarian cancer (platinum-resistant and platinum-
sensitive disease).
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Furthermore, we noted how persistent/recurrent disease
presented: (1) symptomatic (symptoms reported by the
patient, 2) asymptomatic, found only by physical exami-
nation at routine follow-up, (3) asymptomatic, found by
radiologic examination only.
Primary, nodal and distant sites of first failure were
coded as central = C, pelvic sidewall = P, paraaortic
lymph nodes = PA, intraabdominal organs (e.g., perito-
neum, liver parenchyma) = AO, supraclavicular lymph
nodes = SC, and distant = D.
The study was carried out in accordance with the
guidelines of the institutional review board.
Statistical methods
Using the Kaplan–Meier method, disease-specific survival
(DSS) was calculated from the date of diagnosis to the date
of death from cervical cancer, or for patients who remained
alive, to the date of last follow up. Non-malignancy-related
deaths were censored in the statistical analyses according
to the same method used for patients who were alive and
disease-free. Statistical differences between groups in
terms of survival curves were analysed using the log rank
test. In order to predict factors contributing to late toxicity
and treatment failure, logistic regression was performed;
comparisons between nominal parameters were made with
the Fisher exact test. A p value \0.05 was considered
significant. Statistical analyses were performed with R
Development Core Team software, version 2.7.1 (Vienna,
Austria).
Results
The clinicopathologic, treatment and outcome charac-
teristics of the patients included in the study are sum-
marized in Table 1. At the end of the observation period
in October 2009 (median follow-up time of 37 months,
range 5–81 months), 25 patients (19.5%) had died of
cervical cancer. Three patients (2.3%) were alive with
recurrent cervical cancer. 95 patients (74.3%) were alive
and had no clinical evidence of disease. Five women
(3.9%) died of intercurrent illness, none of whom had
any clinical evidence of recurrent cervical cancer at the
time of death.
Late toxicity
We observed 13 patients (10.2%) with grade 3 late toxicity,
none of whom had any evidence of recurrence. These cases
are summarized in Table 1 and are described in more detail
in Table 2. There were no patients with grade 4 toxicity.
The median time from completion of CRT to all clinical
presentations of severe late toxicity (n = 17) was
16.5 months (range 3–72 months); considering only the
first presentation in each patient, the median time was
10 months (range 3–31).
With regard to the development of late toxicity, the
combination of heavy smoking and cardiovascular co-
morbidity was found to be a significant contributing fac-
tor (HR 6.55, 95% CI 0.99–43.49, p = 0.048). Age
(p = 0.577) and disease stage (p = 0.136) appeared to
have no impact.
Persistent/recurrent disease
Twelve patients (9.4%) had persistent disease and 18
patients (14.0%) developed recurrent disease. The
patients of both of these subgroups comprise 23.4% of
our study cohort. The characteristics of both subgroups
are tabulated in Table 1. Of these 30 patients, 25 (83.3%)
died of progressive or metastatic disease and three
patients (10.0%) were still alive with disease at the
conclusion of our data collection. Two patients (6.6%)
were diagnosed with central disease recurrence only, one
diagnosed 4 months and the other 8 months after com-
pletion of treatment. Both women were salvaged surgi-
cally with total abdominal hysterectomy. At the
conclusion of data collection, they were alive with no
evidence of disease at 15 and 18 months following the
surgical procedures.
Of the 18 patients with recurrent disease, eight patients
(44.4%) had their conditions diagnosed within 1 year and
17 patients (94.4%) within 2 years after the completion of
primary therapy.
Table 3 shows timing, detection method and location of
first treatment failure. Compared with the persistence
subgroup, the patients of the recurrence group had signif-
icantly more often multiple sites (66.7 vs. 8.3%,
p = 0.002). While the persistent subgroup showed pre-
dominantly a uniform treatment failure in the central
region, the sites of relapse in the recurrence group were
more often diagnosed outside the pelvis (70.7 vs. 7.7%,
p \ 0.001). A similar distribution was found for the dom-
inant site (65.0 vs. 8.3%, p = 0.003).
Figure 1 shows the DSS for the entire study cohort and
for the patients with persistent and recurrent disease. The
3-year survival rate was 80.3% for the entire study group,
22.2% for the recurrent disease subgroup and 0% for the
persistent disease subgroup (recurrent vs. persistent dis-
ease: p \ 0.001).
Early disease stage (stage I/II vs. stage III/IV: OR 4.46,
95% CI 1.87 to 10.63, p \ 0.001) and severe late toxicity
(p = 0.037) were found to be significant contributing fac-
tors towards a better DSS. Age appeared to have no impact
(p = 0.485).
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Discussion
Outcomes and patterns of failure
The majority of studies which reported recurrence rates and
patterns of recurrence in cervical cancer included patients
with early stage disease treated with radical hysterectomy
alone, or prior to the adoption of chemoradiation [8, 9].
There are still comparatively few series which have eval-
uated failure rates in women treated with CRT [10–12].
The Royal College of Radiologists (RCR) in 2010 pub-
lished the results of a nationwide audit of chemoradio-
therapy for locally advanced cervical cancer [13], showing
that the addition of chemotherapy to radiotherapy
improved survival compared with radiotherapy alone,
without an apparent rise in late treatment complications.
The 3-year DSS for patients undergoing chemoradiother-
apy were reported as 76, 76 and 54% for FIGO Stages IB,
IIB and IIIB, respectively. The 80.3% 3-year DSS of our
entire cohort compares favourably with these outcomes.
Our data support other similar findings that most of the
treatment failures occur within the first 2 years after
completion of therapy and most are symptomatic [8, 9]. In
the current published literature of treatment failure in
cervical cancer, the corresponding cases have not been
further divided. In most of the studies, all cases were
summarized under the collective terms ‘‘recurrence’’ or
‘‘relapse’’. In this study we have differentiated between
persistent or progressive disease at the end of treatment and
true recurrent disease. Our series has shown that there is a
dichotomy of clinical course between persistent and
recurrent disease. Compared with the persistence subgroup,
which had almost exclusively central pelvic disease at the
time of treatment failure diagnosis, the recurrence sub-
group were more likely to have disease recurrence at
multiple sites, often outside the pelvis, and had a signifi-
cantly better survival.
Similar traditional follow-up protocols with approxi-
mately 12–15 visits over a 5-year period are followed
universally [8, 9]. The primary goal of follow-up is to
identify recurrent disease in asymptomatic patients at a
time when it is amenable to curative salvage therapy. Most
authors conclude that this primary goal will not be
achieved by routine clinical follow-up in most patients
[8, 9]. Our data support this pessimistic assessment. Clin-
ical examination found asymptomatic recurrences (i.e., not
reported by the patients) in only two of the cases with
treatment failure. In one case, however, the disease was
found in a supraclavicular lymph node and no curative
treatment was possible. There was only one patient (3.3%
Table 3 Timing, diagnostic method and location of persistent/
recurrent cervical cancer
Persistent
disease,
n = 12
Recurrent
disease,
n = 18
Median time from completion of
treatment to failure (months)
4a (range
0–5)
12 (range
3–49)
Median follow-up time after
diagnosis of persistent/recurrent
disease (months)
4 (range
1–14)
8.5 (range
1–22)
Detection method
Symptomatic 8 (66.7) 12 (66.7)
Asymptomatic, found by physical
exam
– 2 (11.1)
Asymptomatic, found by
radiologic exam
4 (33.3) 4 (22.2)
Multiple sites at first relapse 1 (8.3) 12 (66.7)
Sites at first relapse
All sites 13 34
Central 11 (84.6) 7 (20.5)
Pelvic side wall 1 (7.7) 3 (8.8)
Para-aortic lymph nodes 1 (7.7) 9 (26.5)
Intraabdominal organs – 2 (5.9)
Supraclavicular lymph nodes – 4 (11.8)
Distant sites – 9 (26.5)
Dominant site at first relapseb
Central 11 (91.7) 5 (25.0)
Pelvic side wall – 2 (10.0)
Para-aortic lymph nodes 1 (8.3) 6 (30.0)
Intraabdominal organs – 2 (10.0)
Supraclavicular lymph nodes – 2 (10.0)
Distant sites – 3 (15.0)
a In three cases, a time could not be given because the disease was
already progressive under treatment
b In two cases, there were two dominant sites clinically equal
Fig. 1 Disease-specific survival (DSS) of cervical cancer patients
who had radiotherapy at the North London Gynaecological Cancer
Network. a entire study cohort (n = 128), b patients with persistent
disease (n = 12), c patients with recurrent disease (n = 18). Com-
parison of subgroups B and C: p \ 0.001. ? censored
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of all patients with treatment failure, and 5.5% of the
recurrence group) who was diagnosed with a central pelvic
recurrence during routine follow-up and she subsequently
underwent salvage hysterectomy. In the other case in our
series where curative salvage hysterectomy was under-
taken, treatment failure was diagnosed at the routine
radiologic examination conducted 3 months after comple-
tion of CRT (therefore, classified as disease persistence).
Some of the aims for surveillance in cervical cancer
patients are potentially better met than the primary goal of
recurrence detection, namely to detect and manage compli-
cations and toxicities of treatment, to provide patients with
psychological support and to collect data for research [8, 9].
Radiation-induced severe late toxicity
In approximately one-half of the published studies
regarding CRT, there are no data on late toxicity [1–5]. The
reported prevalence varies significantly (1–23%) [4] with
the largest review reporting a generally accepted preva-
lence of approximately 10% [14]. The RCR audit also
showed an identical crude late Grade 3–4 toxicity rate of
10% [13]. This heterogeneity between the various studies is
not only partly a result of widely different treatment regi-
mens, but also due to a lack of consistency in reporting of
these data. Some authors suggest that there may be sig-
nificant underreporting in terms of late toxicities [1, 4].
Therefore, a meaningful compilation of these cases
requires a systematic and detailed description [15]. In some
cases, this is challenging since the clinical pictures often
overlap and are hard to discriminate from one another. An
example of this is the reporting of fistulae. First, we must
differentiate between those that are radiation-induced (i.e.,
in patients who are free of disease) and those occurring in
the context of progressive disease. In some cases, there
may be a contribution from both treatment effects and
recurrent disease. Second, there may be an overlap with a
spectrum of clinical pictures and severity, some of which
may not fit easily into the current fixed patterns of classi-
fication schemes. It is very rare for patients to develop
severe late toxicity of a particular organ in isolation. Most
patients experience a broad range of mild and moderate
sequelae of other organs as well. Currently, there is
increasing recognition of the effects of persistent low-grade
problems [16]: ‘‘the little things that get us down’’ [17], and
these need to be identified. We utilized the Franco-Italian
glossary score because it is well recognized and gynaeco-
logical cancer specific with detailed descriptions of toxicity
patterns [7]. Nonetheless, it can still be difficult to clearly
separate between moderate and severe complications. This
problem can be illustrated with late toxicity on bowel/
rectum whereby the criteria for severe toxicity are fulfilled
in cases where bleeding requires surgery. With the usage of
endoscopic methods like Argon Plasma Coagulation
treatment for rectal bleeding, the line between when sur-
gery is required and consequently, definition of moderate
or severe toxicity becomes blurred. Perhaps more objective
parameters are required to distinguish the two as thera-
peutic modalities for management of toxicities are con-
stantly evolving.
The development of radiotherapy-related late toxicity is
likely to be multifactorial. Factors identified as possible
contributors include the total dose of radiation and dose per
fraction, large radiation field (which implies advanced
disease stage), medical comorbidities (particularly cardio-
vascular disease), smoking, low body mass index and a
history of abdominal surgery which may lead to a reduction
in the blood supply to the pelvic organs and/or bowel
adhesions [14, 15, 18]. A combination of the aforemen-
tioned risk factors may potentiate the development of
complications.
A potential point of criticism regarding our data could
be the fact that we report on different therapy options and
not exclusively on patients who had radiochemotherapy as
the only treatment (see different therapy forms in Table 1).
However, this subgroup does represent the vast majority of
our study cohort. We found it particularly interesting to
demonstrate patterns of failure and late toxicity, not
focusing on a specific treatment but rather from the per-
spective of the treating clinicians who follow the individual
clinical courses. In doing so, we report rare clinical con-
ditions which would otherwise not be reported and have
not been so up until now. The colleagues who are inter-
ested in the data solely from a homogeneous therapy entity
view can easily access this information from our data.
Conclusions
Differentiating treatment failure of locally advanced cer-
vical cancer into persistent and recurrent disease is useful
as this may allow further study of the patient, tumour and
treatment factors associated with disease persistence. We
hope that our systematic and detailed description of severe
radiotherapy-induced late toxicity will help raise awareness
and recognition of these sequelae and thus reduce under-
reporting. The paucity of information regarding serious late
toxicity highlights the need for prospective evaluations of
outcome, treatment tolerability and quality of life in future
trials [1].
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